IDARUBICIN HYDROCHLORIDE
Post-LOEANDAINTRAVENOUSSOLUTION
Approved
May 2007
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
IDARUBICIN HYDROCHLORIDE by Hikma is dna, inhibiting nucleic acid synthesis, inhibiting topoisomerase ii activity, and producing dna-damaging free radicals. First approved in 2007.
Drug data last refreshed 23h ago
Mechanism of Action
DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Hikma
NJ - Berkeley Heights
Worked on IDARUBICIN HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.